Implandata Ophthalmic Products GmbH, a Hannover, Germany-based ophthalmic medical device company, held the first mid-single digit million Euro closing of its Series C funding round.
Backers included Heidelberg Engineering GmbH/Germany, Occident Group AG/Switzerland and NKB GmbH/Germany, KfW, HTGF, Peppermint Charité Beteiligungsfonds and several private investors and ophthalmologists.
The company intends to complete the Series C-round by raising an upper end single digit million Euro amount by the fall of 2018.
Led by Max Ostermeier, CEO, Implandata is an ISO 13485 certified medical device company, which has developed the CE marked EYEMATE™ system for continuous monitoring of IOP. The EYEMATE system includes a surgically implantable micro-sensor (to be implanted in conjunction with cataract, glaucoma or corneal surgery, eventually also in a stand-alone procedure) for direct measurement of eye pressure. A patient hand-held device for sensor implant powering and data read-out is communicating real-time via internet with eye care specialists (and the patient as well).
The company is expanding its product portfolio with different sensor implant versions, allowing to address the various needs of glaucoma patients.